Electrocore Completes Merger with NeuroMetrix

The latest announcement is out from Electrocore ( (ECOR) ).

On May 2, 2025, electroCore, Inc. announced the completion of its merger with NeuroMetrix, Inc., which positions electroCore as a diversified leader in non-invasive health and wellness solutions. The acquisition of NeuroMetrix’s Quell Fibromyalgia Solution expands electroCore’s portfolio of non-invasive bioelectronic therapies, enhances its commercial reach, particularly within the VA Hospital System, and is expected to significantly increase its addressable market for chronic pain and wellness conditions. As a result of the merger, NeuroMetrix became an indirect wholly-owned subsidiary of electroCore, and its shares will be de-listed from the Nasdaq Capital Market.

Spark’s Take on ECOR Stock

According to Spark, TipRanks’ AI Analyst, ECOR is a Neutral.

Electrocore’s strong revenue growth and strategic advancements are significant positives. However, profitability challenges, a negative P/E ratio, and mixed technical indicators temper the overall outlook.

To see Spark’s full report on ECOR stock, click here.

More about Electrocore

electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through innovative non-invasive bioelectronic technologies.

YTD Price Performance: -54.86%

Average Trading Volume: 150,363

Technical Sentiment Signal: Buy

Current Market Cap: $54.45M

See more data about ECOR stock on TipRanks’ Stock Analysis page.